NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Lithium for Parkinson's: an Extension Trial

NCT06592014

Enrolling By InvitationPhase 1, Phase 2

Sponsor: State University of New York at Buffalo

Conditions: Parkinson Disease

Interventions: Lithium aspartate

Countries: United States

This study will examine the effects of 24 weeks of lithium therapy achieving serum lithium levels of 0.25-0.50mmol/L on MRI and blood-based biomarkers in Parkinson's disease patients who have completed one of our current 24-week lithium clinical trials.

Eligibility overview

Sex: ALL

Age: 45 Years to 80 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

1. All PD patients completing STUDY00007253 or STUDY00008239 at the University at Buffalo will be eligible.
2. No unstable cardiac, medical, neurologic or psychiatric condition in the opinion of the PI.
3. No current use of illicit drugs or current alcohol abuse in the opinion of the PI.
4. No history of brain surgery or possible need for brain surgery including deep brain stimulation (DBS) for at least 24 weeks in the opinion of the PI.
5. Women with child bearing potential will need a negative pregnancy test and not be nursing an infant at screening. Women with child bearing potential will need to report using barrier method or hormonal contraception.
6. Willing and able to sign informed consent and follow study procedures.

Locations (1)

Williamsville, New York, United States